EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine

Louisa Schlachter iD, Denise Beck iD, Ramesh R Boinpally iD, Sven Stodtmann iD

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Louisa Schlachter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders, Models, Biological. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This work aimed to develop an appropriate model to evaluate the exposure–response relationship (ERR) for monthly migraine days (MMD) in atogepant's key migraine prevention clinical trials to support dose selection. The ERR between atogepant concentration and MMD over time was analyzed utilizing data from one phase 2b/3 and three phase 3 studies in patients with episodic or chronic migraine (EM/CM). Several distribution models were evaluated for placebo data, whereas two modified normal distributions were introduced enabling bounded MMD modeling. Exposure metrics and shapes for ERR were tested for the most suitable distribution. Stepwise covariate search, visual predictive checks, and plots of model‐predicted MMD over the range of exposure metrics were utilized in model development, evaluation, and selection. The final MMD exposure–response model was able to model patients with EM/CM simultaneously and was based on a modified normal distribution with E max ERR on C min . The model adequately described the observed data over time. Due to the E max relationship, MMD at Week 9–12 plateaued around their model‐based atogepant C min ‐EC 90 of 3.71 nM, which is similar to most C min exposures seen at the 10 mg once‐daily regimen. All approved atogepant dosages for EM/CM achieve effective concentrations to inhibit the calcitonin gene‐peptide receptor by 90%. Patients who have been failed by conventional oral migraine preventive treatments or patients with a higher baseline MMD may require a longer treatment period to reach atogepant's maximal effect. No significant difference in efficacy was evident in patients exposed to prior oral migraine preventives compared to treatment‐naïve patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersModels, BiologicalAdultFemaleHumansMaleMiddle AgedChronic DiseaseClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDose-Response Relationship, DrugTreatment Outcome

Stichwörter der Autor:innen

atogepantchronic migraineepisodic migraineexposure–responsemigraine daysmigraine prevention

Substanzen

Calcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.

ORCID-Profile: Louisa Schlachter, Denise Beck, Ramesh R Boinpally, Sven Stodtmann

Förderung

  • AbbVie

Zitieren

APA

Schlachter, L., Beck, D., Boinpally, R. R., & Stodtmann, S. (2026). Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70154

Vancouver

Schlachter L, Beck D, Boinpally RR, Stodtmann S. Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70154

BibTeX
@article{Schlachter2026,
  author = {Schlachter, Louisa and Beck, Denise and Boinpally, Ramesh R and Stodtmann, Sven},
  title = {Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70154}
}
Kostenlos starten →